Korro Bio, Inc. 8-K Filing
Ticker: KRRO · Form: 8-K · Filed: Dec 18, 2025 · CIK: 1703647
| Field | Detail |
|---|---|
| Company | Korro Bio, Inc. (KRRO) |
| Form Type | 8-K |
| Filed Date | Dec 18, 2025 |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $425,000, $100,000 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Korro Bio, Inc. (ticker: KRRO) to the SEC on Dec 18, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ch registered Common stock, par value $0.001 per share KRRO The Nasdaq Capital M); $425,000 (for (i) increased annual base salary of $425,000 (reflecting current 2025 base salary);); $100,000 (on program, Dr. Cerio was (i) awarded a $100,000 cash bonus, 50% of which will be paid o).
How long is this filing?
Korro Bio, Inc.'s 8-K filing is 2 pages with approximately 744 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 744 words · 3 min read · ~2 pages · Grade level 12.2 · Accepted 2025-12-18 16:05:25
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share KRRO The Nasdaq Capital M
- $425,000 — for (i) increased annual base salary of $425,000 (reflecting current 2025 base salary);
- $100,000 — on program, Dr. Cerio was (i) awarded a $100,000 cash bonus, 50% of which will be paid o
Filing Documents
- krro-20251215.htm (8-K) — 55KB
- krro-ex10_1.htm (EX-10.1) — 162KB
- 0001193125-25-324795.txt ( ) — 357KB
- krro-20251215.xsd (EX-101.SCH) — 32KB
- krro-20251215_htm.xml (XML) — 5KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1# Amended and Restated Employment Agreement with Jeffrey Cerio, dated effective December 15, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) # Indicates a management contract or any compensatory plan, contract or arrangement.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KORRO BIO, INC. Date: December 18, 2025 By: /s/ Ram Aiyar Name: Ram Aiyar Title: President and Chief Executive Officer and Interim Chief Financial Officer